Form 8-K - Current report:
SEC Accession No. 0001104659-25-057836
Filing Date
2025-06-09
Accepted
2025-06-09 16:13:33
Documents
12
Period of Report
2025-06-06
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2517533d1_8k.htm   iXBRL 8-K 36016
  Complete submission text file 0001104659-25-057836.txt   203723

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20250606.xsd EX-101.SCH 3017
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20250606_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20250606_pre.xml EX-101.PRE 22360
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2517533d1_8k_htm.xml XML 3808
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 251034237
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)